Rybrevant Faspro™(Amivantamab与Hyaluronidase-Lpuj联合方案)一线治疗晚期头颈癌患者,总缓解率达77%

美股速递
Yesterday

Rybrevant Faspro™(Amivantamab与Hyaluronidase-Lpuj联合疗法)在晚期头颈癌患者的一线治疗中,展现出77%的总缓解率。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10